NextGen Sciences Launches Multiplex Protein Plasma Biomarker Assay for Breast Cancer

By Nextgen Sciences, PRNE
Tuesday, April 12, 2011

ANN ARBOR, Michigan and LONDON, April 13, 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary
NextGen Sciences Inc, a leader in biomarker discovery, measurement and
qualification, has launched its plasmabreast25 multiplex protein assay,
targeting breast cancer (
biomarker discovery and qualification. The assay simultaneously measures 25
human plasma proteins that are thought to have potential as biomarkers in
breast cancer.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, "The release
of plasmabreast25 is further indication of our commitment to developing and
marketing multiplex assays (
for biomarker discovery in specific cancer areas. It enables us to remain
focused on increasing our market share from the $600m mass spectrometry based
biomarker discovery market. To ensure we continually deliver the high-quality
assays that pharmaceutical, biotechnology and diagnostics companies need to
inform their decision-making processes, NextGen Sciences is currently
planning more such products in the near future."

NextGen's assay is based upon its multiple reaction monitoring (MRM) mass
spectrometry platform (
and generates high quality reproducible data that companies can use in their
drug and diagnostic development programmes. NextGen expects to develop
further oncology and CNS disease-focused assay panels (, both as proprietary products
and with other companies, through partnerships and collaborations.

    For more information please contact :

    NextGen Group
    Klaus Rosenau, Chairman and CEO

    Seymour Pierce
    Jonathan Wright, Nicola Marrin

Notes to Editors

NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen
Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology
and diagnostic companies with rapid and quantitative protein biomarker
discovery, measurement and qualification services using mass spectrometry
technology. With a rise in the industry focus on personalized medicine and
cost-effectiveness, biomarkers are playing an increasingly important role in
drug discovery, development and patient access, as well as healthcare
delivery. The global market for biomarkers is expected to grow to $12.8bn by
2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015,
Espicom Healthcare) and oncology ($9.5bn by 2014,
playing an important role. NextGen Sciences' products include
discoveryexpress for discovery of new biomarkers and targets, assayexpress
for assay development and testingexpress for biomarker qualification. For
more information visit


will not be displayed